Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (431-440 of 471) with videos related to

Pageof 48
Sort By:
Circulation|March 17, 2004
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)Douglas L Mann, John J V McMurray, Milton Packer, et al.
European Heart Journal|May 8, 2014
Risk stratification for sudden cardiac death: current status and challenges for the futureHein J J Wellens, Peter J Schwartz, Fred W Lindemans, et al.
Health Science Reports|June 18, 2021
Testing cost containment of future healthcare with maintained or improved quality-The COSTCARES projectKarl Swedberg, Desmond Cawley, Inger Ekman, et al.
JAMA|August 10, 2002
Sertraline treatment of major depression in patients with acute MI or unstable anginaAlexander H Glassman, Christopher M O'Connor, Robert M Califf, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Circulation|October 20, 2004
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.
European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.
European Heart Journal|August 25, 2009
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsMarco Metra, Eric Eichhorn, William T Abraham, et al.
European Heart Journal|January 25, 2015
Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysisColette E Jackson, Davide Castagno, Aldo P Maggioni, et al.
Pageof 48

Showing results (431-440 of 471) with videos related to

Sort By:
Pageof 48
Circulation|March 17, 2004
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)Douglas L Mann, John J V McMurray, Milton Packer, et al.
European Heart Journal|May 8, 2014
Risk stratification for sudden cardiac death: current status and challenges for the futureHein J J Wellens, Peter J Schwartz, Fred W Lindemans, et al.
Health Science Reports|June 18, 2021
Testing cost containment of future healthcare with maintained or improved quality-The COSTCARES projectKarl Swedberg, Desmond Cawley, Inger Ekman, et al.
JAMA|August 10, 2002
Sertraline treatment of major depression in patients with acute MI or unstable anginaAlexander H Glassman, Christopher M O'Connor, Robert M Califf, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Circulation|October 20, 2004
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.
European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.
European Heart Journal|August 25, 2009
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsMarco Metra, Eric Eichhorn, William T Abraham, et al.
European Heart Journal|January 25, 2015
Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysisColette E Jackson, Davide Castagno, Aldo P Maggioni, et al.
Pageof 48